Heat-shock protein vaccines as active immunotherapy against human gliomas

Isaac Yang, Seunggu (Jude) Han, Andrew T. Parsa

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Modern advances in cancer immunotherapy have led to the development of active immunotherapy that utilizes tumor-associated antigens to induce a specific immune response against the tumor. Current methods of immunotherapy implementation are based on the principle that tumor-associated antigens are capable of being processed by antigen-presenting cells and inducing an activated cytotoxic T-lymphocyte-specific immune response that targets the tumor cells. Antigen internalization and processing by antigen-presenting cells, such as dendritic cells, or macrophages results in their surface association with MHC class I molecules, which can be recognized by an antigen-specific cytotoxic T-lymphocyte adaptive immune response. With the aim of augmenting current immunotherapeutic modalities, much effort has been directed towards enhancing antigen-presenting cell activation and optimizing the processing of tumor-associated antigens and major histocompatibility molecules. The goal of these immunotherapy modifications is to ultimately improve the adaptive specific immune response in killing of tumor cells while sparing normal tissues. Immunotherapy has been actively studied and applied in glioblastomas. Preclinical animal models have shown the feasibility of an active immunotherapy approach through the utilization of tumor vaccines, and recently several clinical studies have also been initiated. Recently, endogenous heat-shock proteins have been implicated in the mediation of both the adaptive and innate immune responses. They are now being investigated as a potential modality and adjuvant to immunotherapy, and they represent a promising novel treatment for human glioblastomas.

Original languageEnglish (US)
Pages (from-to)1577-1582
Number of pages6
JournalExpert review of anticancer therapy
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Active Immunotherapy
Heat-Shock Proteins
Glioma
Immunotherapy
Vaccines
Adaptive Immunity
Neoplasm Antigens
Antigen-Presenting Cells
Cytotoxic T-Lymphocytes
Glioblastoma
Neoplasms
Cancer Vaccines
Histocompatibility
Antigen Presentation
Innate Immunity
Dendritic Cells
Animal Models
Macrophages
Antigens

Keywords

  • Active immune response
  • Antigen
  • Antigen-presenting cells
  • Cancer vaccines
  • CTL
  • Heat-shock proteins
  • Immunotherapy
  • T-cell lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Heat-shock protein vaccines as active immunotherapy against human gliomas. / Yang, Isaac; Han, Seunggu (Jude); Parsa, Andrew T.

In: Expert review of anticancer therapy, Vol. 9, No. 11, 01.11.2009, p. 1577-1582.

Research output: Contribution to journalReview article

@article{fb39a32d366d4200b9f44eb45c869435,
title = "Heat-shock protein vaccines as active immunotherapy against human gliomas",
abstract = "Modern advances in cancer immunotherapy have led to the development of active immunotherapy that utilizes tumor-associated antigens to induce a specific immune response against the tumor. Current methods of immunotherapy implementation are based on the principle that tumor-associated antigens are capable of being processed by antigen-presenting cells and inducing an activated cytotoxic T-lymphocyte-specific immune response that targets the tumor cells. Antigen internalization and processing by antigen-presenting cells, such as dendritic cells, or macrophages results in their surface association with MHC class I molecules, which can be recognized by an antigen-specific cytotoxic T-lymphocyte adaptive immune response. With the aim of augmenting current immunotherapeutic modalities, much effort has been directed towards enhancing antigen-presenting cell activation and optimizing the processing of tumor-associated antigens and major histocompatibility molecules. The goal of these immunotherapy modifications is to ultimately improve the adaptive specific immune response in killing of tumor cells while sparing normal tissues. Immunotherapy has been actively studied and applied in glioblastomas. Preclinical animal models have shown the feasibility of an active immunotherapy approach through the utilization of tumor vaccines, and recently several clinical studies have also been initiated. Recently, endogenous heat-shock proteins have been implicated in the mediation of both the adaptive and innate immune responses. They are now being investigated as a potential modality and adjuvant to immunotherapy, and they represent a promising novel treatment for human glioblastomas.",
keywords = "Active immune response, Antigen, Antigen-presenting cells, Cancer vaccines, CTL, Heat-shock proteins, Immunotherapy, T-cell lymphocytes",
author = "Isaac Yang and Han, {Seunggu (Jude)} and Parsa, {Andrew T.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1586/ERA.09.104",
language = "English (US)",
volume = "9",
pages = "1577--1582",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Heat-shock protein vaccines as active immunotherapy against human gliomas

AU - Yang, Isaac

AU - Han, Seunggu (Jude)

AU - Parsa, Andrew T.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Modern advances in cancer immunotherapy have led to the development of active immunotherapy that utilizes tumor-associated antigens to induce a specific immune response against the tumor. Current methods of immunotherapy implementation are based on the principle that tumor-associated antigens are capable of being processed by antigen-presenting cells and inducing an activated cytotoxic T-lymphocyte-specific immune response that targets the tumor cells. Antigen internalization and processing by antigen-presenting cells, such as dendritic cells, or macrophages results in their surface association with MHC class I molecules, which can be recognized by an antigen-specific cytotoxic T-lymphocyte adaptive immune response. With the aim of augmenting current immunotherapeutic modalities, much effort has been directed towards enhancing antigen-presenting cell activation and optimizing the processing of tumor-associated antigens and major histocompatibility molecules. The goal of these immunotherapy modifications is to ultimately improve the adaptive specific immune response in killing of tumor cells while sparing normal tissues. Immunotherapy has been actively studied and applied in glioblastomas. Preclinical animal models have shown the feasibility of an active immunotherapy approach through the utilization of tumor vaccines, and recently several clinical studies have also been initiated. Recently, endogenous heat-shock proteins have been implicated in the mediation of both the adaptive and innate immune responses. They are now being investigated as a potential modality and adjuvant to immunotherapy, and they represent a promising novel treatment for human glioblastomas.

AB - Modern advances in cancer immunotherapy have led to the development of active immunotherapy that utilizes tumor-associated antigens to induce a specific immune response against the tumor. Current methods of immunotherapy implementation are based on the principle that tumor-associated antigens are capable of being processed by antigen-presenting cells and inducing an activated cytotoxic T-lymphocyte-specific immune response that targets the tumor cells. Antigen internalization and processing by antigen-presenting cells, such as dendritic cells, or macrophages results in their surface association with MHC class I molecules, which can be recognized by an antigen-specific cytotoxic T-lymphocyte adaptive immune response. With the aim of augmenting current immunotherapeutic modalities, much effort has been directed towards enhancing antigen-presenting cell activation and optimizing the processing of tumor-associated antigens and major histocompatibility molecules. The goal of these immunotherapy modifications is to ultimately improve the adaptive specific immune response in killing of tumor cells while sparing normal tissues. Immunotherapy has been actively studied and applied in glioblastomas. Preclinical animal models have shown the feasibility of an active immunotherapy approach through the utilization of tumor vaccines, and recently several clinical studies have also been initiated. Recently, endogenous heat-shock proteins have been implicated in the mediation of both the adaptive and innate immune responses. They are now being investigated as a potential modality and adjuvant to immunotherapy, and they represent a promising novel treatment for human glioblastomas.

KW - Active immune response

KW - Antigen

KW - Antigen-presenting cells

KW - Cancer vaccines

KW - CTL

KW - Heat-shock proteins

KW - Immunotherapy

KW - T-cell lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=71949119442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949119442&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.104

DO - 10.1586/ERA.09.104

M3 - Review article

C2 - 19895242

AN - SCOPUS:71949119442

VL - 9

SP - 1577

EP - 1582

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -